Form 4: Corcept Therapeutics Executive William Guyer Reports Stock Transactions

William Guyer, Chief Development Officer of Corcept Therapeutics, reports the acquisition and disposal of common stock and stock options on April 1, 2025, according to a Form 4 filing.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On April 1, 2025, Guyer exercised stock options to acquire 678 shares of common stock at a price of $21.65 per share.
• Simultaneously, Guyer sold 678 shares of common stock at a weighted average price of $114.5118 per share, with individual sale prices ranging from $114.29 to $114.71.
• Following these transactions, Guyer directly owns 5,487 shares of common stock and 449,322 stock options.
• The stock sale was executed under a pre-arranged 10b5-1 trading plan adopted on November 27, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a routine disclosure of stock transactions under a pre-arranged plan. While executive stock sales can sometimes raise concerns, the existence of the 10b5-1 plan mitigates potential negative interpretations.

Positives

• The filing indicates that the executive is exercising stock options, which could be seen as a positive sign of confidence in the company's future.

Negatives

• The sale of shares by an executive could be interpreted negatively by some investors, although it is part of a pre-arranged trading plan.

Risks

• Executive stock sales can sometimes create uncertainty among investors, even when conducted under a 10b5-1 plan.

Future Outlook

The document does not contain specific forward-looking statements, but it does indicate continued execution of a pre-arranged trading plan.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• Executive compensation and trading activities are generally benchmarked against peer companies in the biotechnology and pharmaceutical industries.
• Companies like Gilead Sciences, Amgen, and Biogen are often used as comparables for executive compensation analysis.
• The use of 10b5-1 trading plans is a standard practice among executives to avoid accusations of insider trading.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholders, depending on how they interpret the executive's trading activity.

Key Dates

Keywords

Form 4, Corcept Therapeutics, CORT, William Guyer, Stock Options, Beneficial Ownership, 10b5-1 Plan, Executive Compensation